BML Capital Management
Latest statistics and disclosures from BML Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ACRS, AVIR, ADVM, TIL, ORMP, and represent 75.53% of BML Capital Management's stock portfolio.
- Added to shares of these 10 stocks: TIL, Connect Biopharma Hldgs, Imagenebio, Athira Pharma, TGT, WMT, ARVN, PMVP, KZR, ORMP.
- Started 7 new stock positions in MURA, ARVN, WMT, Connect Biopharma Hldgs, Athira Pharma, TGT, Imagenebio.
- Reduced shares in these 10 stocks: EPIX (-$7.2M), IKNA (-$5.4M), MIST, ELEV, CNTB, , ATHA, CRVS, TSBX, AVIR.
- Sold out of its positions in ATHA, CNTB, CRVS, ELEV, EPIX, Hillevax, IKNA, MIST, TSLA, TSBX. Verrica Pharmaceuticals.
- BML Capital Management was a net seller of stock by $-14M.
- BML Capital Management has $109M in assets under management (AUM), dropping by -17.37%.
- Central Index Key (CIK): 0001616824
Tip: Access up to 7 years of quarterly data
Positions held by BML Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for BML Capital Management
BML Capital Management holds 20 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Aclaris Therapeutics (ACRS) | 24.8 | $27M | 14M | 1.90 |
|
|
| Atea Pharmaceuticals (AVIR) | 19.8 | $22M | 7.5M | 2.90 |
|
|
| Adverum Biotechnologies Com New (ADVM) | 12.7 | $14M | 3.1M | 4.53 |
|
|
| Instil Bio Com New (TIL) | 10.6 | $12M | +20% | 646k | 17.86 |
|
| Oramed Pharmaceuticals Com New (ORMP) | 7.7 | $8.4M | +2% | 3.2M | 2.64 |
|
| Pmv Pharmaceuticals (PMVP) | 6.8 | $7.4M | +5% | 5.3M | 1.40 |
|
| Alumis (ALMS) | 4.4 | $4.8M | 1.2M | 3.99 |
|
|
| Lava Therapeutics Nv SHS (LVTX) | 2.8 | $3.1M | 2.0M | 1.56 |
|
|
| Kezar Life Sciences Com New (KZR) | 2.6 | $2.8M | +13% | 721k | 3.90 |
|
| Connect Biopharma Hldgs SHS | 1.8 | $1.9M | NEW | 1.3M | 1.51 |
|
| Imagenebio | 1.4 | $1.5M | NEW | 183k | 8.15 |
|
| Athira Pharma | 1.2 | $1.3M | NEW | 323k | 4.14 |
|
| Astrotech Corp (ASTC) | 1.0 | $1.1M | 220k | 4.90 |
|
|
| Target Corporation (TGT) | 0.8 | $897k | NEW | 10k | 89.70 |
|
| Vistagen Therapeutics Ord (VTGN) | 0.5 | $533k | 150k | 3.55 |
|
|
| Wal-Mart Stores Put Option (WMT) | 0.5 | $519k | NEW | 265.00 | 1957.50 |
|
| Arvinas Ord (ARVN) | 0.4 | $426k | NEW | 50k | 8.52 |
|
| Lisata Therapeutics (LSTA) | 0.3 | $288k | -47% | 110k | 2.62 |
|
| Mural Oncology Pub Ord Shs (MURA) | 0.1 | $119k | NEW | 58k | 2.07 |
|
| Third Harmonic Bio (THRD) | 0.0 | $0 | 3.8M | 0.00 |
|
Past Filings by BML Capital Management
SEC 13F filings are viewable for BML Capital Management going back to 2022
- BML Capital Management 2025 Q3 filed Nov. 10, 2025
- BML Capital Management 2025 Q2 filed Aug. 11, 2025
- BML Capital Management 2025 Q1 filed May 7, 2025
- BML Capital Management 2024 Q4 filed Feb. 7, 2025
- BML Capital Management 2024 Q3 filed Nov. 5, 2024
- BML Capital Management 2024 Q2 filed Aug. 7, 2024
- BML Capital Management 2024 Q1 restated filed April 24, 2024
- BML Capital Management 2024 Q1 filed April 23, 2024
- BML Capital Management 2023 Q4 restated filed Feb. 2, 2024
- BML Capital Management 2023 Q4 filed Jan. 30, 2024
- BML Capital Management 2023 Q3 filed Oct. 23, 2023
- BML Capital Management 2023 Q2 filed July 24, 2023
- BML Capital Management 2023 Q1 filed April 14, 2023
- BML Capital Management 2022 Q4 filed Feb. 13, 2023